SECsense Logo

Travere Therapeutics 8-K Report: Key Insights & Updates for Investors

$TVTX
Form 8-K
Filed on: 2025-02-20
Source
Travere Therapeutics 8-K Report: Key Insights & Updates for Investors

Here are the key insights extracted from the provided financial report section:

  1. Company Information:
  • Name: Travere Therapeutics, Inc.
  • CIK: 0001438533
  • Industry Classification: 3611 (Pharmaceuticals)
  • Headquarters: 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130
  • Contact Number: 888-969-7879
  1. SEC Filing Details:
  • Filing Type: 8-K (Current Report)
  • Filing Date: February 20, 2025
  1. Stock Information:
  • Common Stock: Par value of $0.0001 per share
  • Ticker Symbol: TVTX
  • Exchange: NASDAQ
  1. Period of Report:
  • Report Date: February 20, 2025
  1. Document Structure:
  • The report is structured in XBRL (eXtensible Business Reporting Language), which facilitates the electronic filing and reporting of financial data.

This information is crucial for stakeholders to understand the company's current operations, its market presence, and any significant events or changes reported in the 8-K filing.